Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
11.06. | Genentech lays off 143 workers at South San Francisco campus | ||
11.06. | Merck KGaA's MilliporeSigma teams with Simtra in ADC manufacturing partnership | ||
11.06. | Pharmas to face higher drug rebates in UK despite government's tweak to proposal | ||
10.06. | Oxford taps CDMO Recipharm to handle additional manufacturing work in malaria vaccine collab | ||
10.06. | 'All innuendo and conspiracy'-RFK Jr.'s vaccine advisory overhaul undermines vaccine confidence, experts say | ||
10.06. | Travere taps Grammy-winning producer to create anthem for kidney disease patients | ||
10.06. | Insmed's 'unprecedented' phase 2 PAH win sends stocks soaring as the race to phase 3 kicks off | ||
10.06. | NATO for medicines? Pfizer CEO calls for higher drug spending outside US amid Trump's MFN pricing push | ||
10.06. | TV drug ad spending continued downward slope in May, with AbbVie's Skyrizi hanging on to top spot | ||
10.06. | National Resilience will close 6 of its 10 plants and carry on as streamlined CDMO | ||
09.06. | Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus | ||
09.06. | 'Time to Listen': Pfizer debuts video series about life with sickle cell disease | ||
09.06. | Abcuro hires ex-Alexion, Biohaven exec to lead commercial team ahead of planned launch | ||
09.06. | Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate | ||
09.06. | Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus | ||
09.06. | George Medicines opens new front in hypertension treatment with FDA nod for combo pill | ||
09.06. | FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer | ||
09.06. | WuXi Biologics breaks ground on microbial production plant in China | ||
09.06. | Swedish contract manufacturer Rechon hit with FDA warning letter for unsanitary conditions | ||
06.06. | Argenx joins NBC health marketing platform to produce CIDP reality show | ||
06.06. | Novartis presses court for hasty decision in long-running Entresto patent feud with MSN | ||
06.06. | In response to FDA safety review of mifepristone, 4 pro-abortion states hit back | ||
05.06. | Swiss CDMO Carbogen bolsters ADC production capability with $31M investment | ||
05.06. | Orca hires ex-Legend exec Gavel to hammer open cell therapy market | ||
05.06. | Newly proposed EU drug regulations a 'missed opportunity' to support innovation, industry says |